Zacks Research Predicts Lower Earnings for AngioDynamics

AngioDynamics, Inc. (NASDAQ:ANGO) – Zacks Research decreased their Q3 2026 earnings per share (EPS) estimates for shares of AngioDynamics in a research note issued to investors on Tuesday, January 27th. Zacks Research analyst Team now forecasts that the medical instruments supplier will earn ($0.10) per share for the quarter, down from their prior forecast of ($0.08). Zacks Research currently has a “Strong-Buy” rating on the stock. The consensus estimate for AngioDynamics’ current full-year earnings is ($0.37) per share. Zacks Research also issued estimates for AngioDynamics’ Q4 2026 earnings at ($0.07) EPS, Q1 2027 earnings at ($0.08) EPS, Q2 2027 earnings at ($0.05) EPS, Q3 2027 earnings at $0.03 EPS, Q4 2027 earnings at ($0.04) EPS, FY2027 earnings at ($0.13) EPS, Q1 2028 earnings at ($0.03) EPS and Q2 2028 earnings at ($0.02) EPS.

A number of other equities research analysts have also recently commented on the stock. Canaccord Genuity Group upped their target price on shares of AngioDynamics from $17.00 to $18.00 and gave the company a “buy” rating in a report on Friday, October 3rd. Wall Street Zen cut AngioDynamics from a “buy” rating to a “hold” rating in a research report on Sunday, December 21st. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AngioDynamics in a research report on Wednesday, January 21st. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, AngioDynamics has an average rating of “Moderate Buy” and an average target price of $19.33.

AngioDynamics Price Performance

Shares of NASDAQ:ANGO opened at $10.36 on Thursday. AngioDynamics has a 1-year low of $8.27 and a 1-year high of $13.99. The stock has a market cap of $427.04 million, a P/E ratio of -15.46 and a beta of 0.47. The firm has a fifty day moving average price of $12.06 and a 200 day moving average price of $11.08.

AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings data on Tuesday, January 6th. The medical instruments supplier reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.05). The firm had revenue of $79.43 million during the quarter, compared to analysts’ expectations of $76.43 million. AngioDynamics had a negative net margin of 9.02% and a negative return on equity of 2.28%. AngioDynamics’s quarterly revenue was up 9.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.04) EPS. AngioDynamics has set its FY 2026 guidance at -0.330–0.230 EPS.

Institutional Trading of AngioDynamics

Hedge funds have recently modified their holdings of the business. State of Alaska Department of Revenue acquired a new position in AngioDynamics during the third quarter worth $25,000. Farther Finance Advisors LLC grew its stake in shares of AngioDynamics by 146.4% during the 4th quarter. Farther Finance Advisors LLC now owns 2,018 shares of the medical instruments supplier’s stock worth $26,000 after purchasing an additional 1,199 shares during the period. Washington Trust Advisors Inc. purchased a new position in shares of AngioDynamics in the 3rd quarter valued at about $27,000. State of Wyoming acquired a new position in AngioDynamics during the second quarter worth about $31,000. Finally, Russell Investments Group Ltd. increased its holdings in AngioDynamics by 329.5% in the third quarter. Russell Investments Group Ltd. now owns 4,188 shares of the medical instruments supplier’s stock valued at $47,000 after buying an additional 3,213 shares in the last quarter. 89.43% of the stock is owned by institutional investors and hedge funds.

Key AngioDynamics News

Here are the key news stories impacting AngioDynamics this week:

• Positive Sentiment: Zacks publishes a bullish technical piece saying ANGO has formed a hammer pattern — a potential bottom/support signal that could attract short-term technical buyers and trigger a reversal. Here’s Why AngioDynamics (ANGO) Is a Great ‘Buy the Bottom’ Stock Now
• Positive Sentiment: Zacks also ran a fundamentals-focused piece pointing to solid fiscal Q2 results, accelerating NanoKnife adoption in prostate cancer, and favorable med‑tech margin trends — news that supports revenue growth and longer‑term margin improvement. Reasons to Add AngioDynamics Stock to Your Portfolio for Now
• Positive Sentiment: Zacks Research reiterated a “Strong‑Buy” and raised several forward estimates (including FY2027 from -$0.18 to -$0.13 and upgrades to certain quarters such as Q3 2027 and Q1 2027), which can support sentiment and buy-side conviction for a recovery.
• Neutral Sentiment: Reported short-interest data for January appears invalid (0 shares / NaN change), so there’s no clear indication that a short-covering squeeze is behind today’s move. Investors should treat the short‑interest item as unreliable until corrected.
• Negative Sentiment: Zacks Research also cut several near-term quarterly EPS estimates (multiple revisions trimming Q3/Q4 2026 and Q2 2027 forecasts), signaling potential near-term earnings pressure despite revenue growth — a factor that could cap upside until margins or guidance improve. AngioDynamics Analyst Notes

AngioDynamics Company Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.